UNSPSC 51351705: Trioxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C30H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, R0130F043H chemically known as 3,4-dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl ketone but generally known as trioxifene, which bears US NIH Compound Identifier 50139. European Medicines Agency schedules Trioxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11317MIG.

UNSPSC 51351705 Trioxifene is a Commodity code encompassing pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure trioxifene and related generic pharmaceuticals as part of broader multi-source drug product contracts that reach health care facilities, correctional institutions, social service agencies, and other public bodies across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body, operating as a multi-state vehicle that coordinates pharmaceutical procurement for member states including Oregon and other participating jurisdictions. Vendors competing under this code must maintain relationships with authorized wholesale distributors (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and offer flexible pricing models including flat price, net price formats, and WAC-minus structures. Insurance requirements include $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability per occurrence.

The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026, seeking multiple contract awards for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The procurement structure prioritizes price competitiveness (75 percent of evaluation weight), with additional scoring for fixed pricing, administrative fee compliance, EDI capability, and willingness to accept a 3 percent administrative fee on all purchases. Products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026, and a two-year initial contract term with optional extensions. The RFP does not disclose a specific budget ceiling or award values. Vendors are evaluated in part on therapeutic considerations, product availability, and patient safety, and MMCAP reserves the right to make sole, dual, or multi-awards. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.